erythema Clinical Trials in Barcelona
18 recruitingBarcelona, Spain
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled233 locationsNCT06617325
Recruiting
Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled57 locationsNCT06570798
Recruiting
Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled138 locationsNCT07409181
Recruiting
Phase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AstraZeneca245 enrolled103 locationsNCT07430306
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled65 locationsNCT07175285
Recruiting
Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled222 locationsNCT07438496
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled143 locationsNCT06133972
Recruiting
Phase 1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Rheumatoid ArthritisSystemic Lupus Erythematosus
AstraZeneca48 enrolled33 locationsNCT07201558
Recruiting
Phase 1
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Systemic Lupus Erythematosus
GlaxoSmithKline44 enrolled19 locationsNCT07371468
Recruiting
Anifrolumab Malignancy and Serious Infections Study
Systemic Lupus Erythematosus
AstraZeneca3,195 enrolled4 locationsNCT07000110
Recruiting
Phase 1
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Systemic Lupus Erythematosus
GlaxoSmithKline142 enrolled28 locationsNCT06576271
Recruiting
Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled101 locationsNCT06581198
Recruiting
Phase 4
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
GlaxoSmithKline350 enrolled114 locationsNCT06411249
Recruiting
Phase 1
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Systemic Lupus Erythematosus (SLE)
Novartis Pharmaceuticals54 enrolled13 locationsNCT06335979
Recruiting
Phase 2Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
AstraZeneca302 enrolled272 locationsNCT06015737
Recruiting
Phase 1
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Autolus Limited18 enrolled6 locationsNCT06333483
Recruiting
Phase 1
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520